MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
2.070
-0.030
-1.43%
After Hours: 2.070 0 0.00% 18:17 06/23 EDT
OPEN
2.030
PREV CLOSE
2.100
HIGH
2.170
LOW
2.030
VOLUME
4.81M
TURNOVER
--
52 WEEK HIGH
4.460
52 WEEK LOW
0.9842
MARKET CAP
714.20M
P/E (TTM)
-2.6946
1D
5D
1M
3M
1Y
5Y
1D
Allogene Launches ATM Offering to Bolster Capital Flexibility
TipRanks · 1d ago
Allogene stockholders approve increase in authorized common shares to 800 million
PUBT · 1d ago
Weekly Report: what happened at ALLO last week (0615-0619)?
Weekly Report · 1d ago
Weekly Report: what happened at ALLO last week (0608-0612)?
Weekly Report · 06/15 09:48
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
NASDAQ · 06/12 15:30
Weekly Report: what happened at ALLO last week (0601-0605)?
Weekly Report · 06/08 09:46
Weekly Report: what happened at ALLO last week (0525-0529)?
Weekly Report · 06/01 09:48
Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Immunovant (IMVT)
TipRanks · 05/29 12:30
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.